Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation

Published: September 2016
No. of Pages: 73
Single User License: US $ 6995
Corporate User License: US $ 20985

Glioblastoma multiforme (GBM) is the most common and aggressive type of human brain tumor, accounting for 15.4% of all primary brain tumors. GBM constitutes 60–75% of all astrocytomas – a cancer of the brain originating in a particular type of glial cell in the cerebrum called astrocytes (NCI, 2013a; ABTA, 2016a). It is most common in the elderly, with a peak incidence rate between the ages of 55 and 84, and a median age of diagnosis of 64 (Nelson et al., 2012; Thakkar et al., 2014).

Glioblastoma multiforme (GBM) has a low incidence and prevalence population in the US and EU, with the annual incidence estimated to be three to four cases per 100,000 people. There is a poor prognosis associated with the current standard of care, which is surgical resection followed by radiation therapy and temozolomide chemotherapy, with an associated median survival duration of 12–14 months (Johnson and O’Neill, 2011). There is a limited number of approved drugs for GBM, and these are subject to regional variations. Gliadel and temozolomide are the most widely approved globally, and are cytotoxic chemotherapies that are associated with more toxicity than targeted treatments.

The GBM cancer pipeline is moderately sized, with 512 products active across all stages of development. The range of mechanisms of action employed by these compounds is also highly diverse, especially in comparison with the existing market landscape. More pertinently, there is a large proportion of breakthrough innovations in this pipeline.

It is identified that 120 first-in-class programs in the GBM pipeline, acting on 86 first-in-class molecular targets. This accounts for 31% of all products with a disclosed molecular target, and reflects the high degree of innovation in this indication.

The report “Frontier Pharma: Glioblastoma Multiforme - Cancer Immunotherapies Dominate First-in-Class Product Innovation” analyzes innovation in GBM, in the context of the overall pipeline and current market landscape. In addition, it analyzes the deals landscape surrounding first-in-class products, and pinpoints opportunities for in-licensing.

In particular, this report includes analysis of the following:

• Provides a brief introduction to GBM, including symptoms, pathophysiology, and an overview of pharmacotherapy and treatment algorithms

• Provides comprehensive analysis of the pipeline for first-in-class therapies, analyzed on the basis of stage of development, molecule type and molecular target.

• This report help to Identify and assessment of first-in-class molecular targets, with a particular focus on early-stage programs for which clinical utility has yet to be evaluated, as well as literature reviews on novel molecular targets.

Published By: GBI Research
Product Code: GBI Research1570

Did you find what you are/were looking for ? If not, read below and browse through other relevant pages for similar market research reports OR get in touch with us through the form/contact info in your right navigation panel and well share relevant market report titles for you to explore.

Related Reports:


  • 500,000 market research reports and growing.
  • Top Fortune 500 Organizations trust us for research data.
  • 24/7 support on call as well as emails.
  • Your Details are safe with us.
  • Free support for your research requirements.
  • Report Delivery: Email
  • Delivery Time:
    • Upto 24 hrs - working days
    • Upto 48 hrs max - weekends and public holidays

Research Support / Custom Research

If this business study does not have the data and information analysis you need, contact us with your research requirements. We explore available market research reports to map your needs and share report titles with you. Alternatively, we can also offer custom research that suits your budget and timelines. Share your information requirements here.
Connect With Us
Email: Call : + 1 888 391 5441

Subscription Option

Using our subscription option, you get access to market research reports and industry data of Consumer Goods market as per your needs. Get the best of Consumer Goods research reports by utilizing your research budgets in an optimum way.

More about our Subscription option
Report Alerts

Get Email alerts about market research reports from industries and publishers of your interest: